A phase II study of WT1-W10 peptide vaccine monotherapy for patients with previously-treated advanced Non-Small Cell Lung Cancer - A phase II study of WT1 vaccine for previously-treated NSCLC

Kochi University, School of Medicine, Department of Hematology and Resporatory Medicine0 个研究点目标入组 29 人开始时间: 2014年5月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with active concomitant malignancy. 2) Patients with active and severe infection, requiring intravenous antibiotics and/or anti fungal agents. 3) Patients with active lung disease such as idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug-induced pneumonitis, and considered as inappropriate for the study by the physicians. 4) Patients with uncontrollable complications (e.g. uncontrollable heart disease, uncontrollable effusion and/or pericardial effusion, symptomatic brain metastasis, severe arrhythmia, and so on). 5) Pregnancy or lactation. 6) Patients with mental disorder, and considered as inappropriate for the study by the physicians. 7) Inappropriate patients for this study judged by the physicians.

发起方

Kochi University, School of Medicine, Department of Hematology and Resporatory Medicine